Daicel Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DACHF research report →
Companywww.daicel.com
Daicel Corporation engages in the medical/healthcare, smart, safety, materials, engineering plastics, and other businesses in Japan, China, and internationally. The company offers 1,3-Butylene glycol and polyglycerin for cosmetics; chiral and achiral columns/stationary phases, analytical tools, analytical/purification/synthesis/formulation services, chiral and bio reagents, analytical standards, and DNA and RNA-based probes; triacetylcellulose, high performance film, solvent for electronic materials, polymer for resist, semiconductor process cleaning agent, optical parts and lens unit, silver nanoparticle ink, and organic semiconductor devices; and inflators, pyro-fuse, and safety device for non-mobility products; and acetic acid and derivatives, cellulose acetate, acetate tow, cycloaliphatic epoxies, caprolactone, ketene derivatives, and alkylamines. It also provides ceramide derived from konjac root, equol derived from soybeans, ß-cryptoxanthin derived from citrus unshiu, and lactobionic acid derived from milk; DiSPERZiSTA, a dispersible filler for dietary supplement tablet; and MOiSTCARM, a make granules easy to swallow.
- CEO
- Yasuhiro Sakaki
- IPO
- 2012
- Employees
- 11,134
- HQ
- Osaka, JP
Price Chart
Valuation
- Market Cap
- $2.04B
- P/E
- 30.40
- P/S
- 0.51
- P/B
- 0.87
- EV/EBITDA
- 6.25
- Div Yield
- 5.14%
Profitability
- Gross Margin
- 25.24%
- Op Margin
- 7.26%
- Net Margin
- 1.76%
- ROE
- 2.75%
- ROIC
- 2.63%
Growth & Income
- Revenue
- $583.28B · -0.55%
- Net Income
- $10.25B · -79.29%
- EPS
- $38.35 · -78.86%
- Op Income
- $42.33B
- FCF YoY
- -88.00%
Performance & Tape
- 52W High
- $10.69
- 52W Low
- $8.00
- 50D MA
- $8.44
- 200D MA
- $8.46
- Beta
- 0.53
- Avg Volume
- 1
Get TickerSpark's AI analysis on DACHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our DACHF Coverage
We haven't published any research on DACHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DACHF Report →